MODEX THERAPEUTICS

Modex Therapeutics

#SimilarOrganizations #People #More

MODEX THERAPEUTICS

Industry:
Biotechnology Therapeutics

Status:
Active


Similar Organizations

not_available_image

BliNK Therapeutics

BliNK Therapeutics

escend-pharmaceuticals-logo

Escend Pharmaceuticals

Escend Pharmaceuticals offers cancer therapeutics services.

not_available_image

Insusense Therapeutics

Insusense Therapeutics.

minutia-logo

Minutia

Biotech, Therapeutics

taime-out-massage-studios-logo

Taime Out Massage Studios

Body Contouring & Therapeutic Massage

not_available_image

Traxion Therapeutics Inc

Traxion Therapeutics Inc

Current Employees Featured

patrick-aebischer_image

Patrick Aebischer
Patrick Aebischer Founder @ Modex Therapeutics
Founder
1996-01-01

Founder


patrick-aebischer_image

Patrick Aebischer

More informations about "Modex Therapeutics"

ModeX Therapeutics

Our modular platforms unite the power of multiple biologics into single molecules to combat complex diseases. Over decades, our leaders have served at the highest levels of academia, …See details»

About Us » ModeX Therapeutics

ModeX is dedicated to developing next-generation multispecific biologics for cancers and infectious diseases. ModeX’s platforms unite the power of multiple biologics in a single …See details»

Pipeline - ModeX Therapeutics

Modex multispecific advantage MDX2001 is a tetraspecific antibody designed to optimize T cell function while preventing tumor antigen escape. Our multispecific antibody format allows MDX2001 to simultaneously engage with two T cell …See details»

ModeX Therapeutics - Crunchbase Company Profile

View contacts for ModeX Therapeutics to access new leads and connect with decision-makers. ModeX Therapeutics is a manufacturer and developer of immune therapy drugs. ModeX Therapeutics was acquired by OPKO Health …See details»

ModeX Therapeutics Company Profile 2024: Valuation, …

Manufacturer and developer of immune therapy drugs. The company provides cancer immunotherapies, multi-specific antibody for HIV and SARS-CoV-2, tumor-specific killing antibody and an underdeveloped vaccine for Epstein …See details»

Modex Therapeutics - Crunchbase Company Profile & Funding

Modex Therapeutics provides a platform that unites the power of multiple biologics into single molecules to combat complex diseases. Modex Therapeutics is headquartered in Strathmore …See details»

ModeX Therapeutics Secures BARDA Contract to Develop Novel ...

Sep 28, 2023 · MSTAR is a flexible plug-and-play platform able to incorporate four to six independent antibody binding sites into a single molecule, dramatically expanding their …See details»

ModeX Therapeutics Secures $35 Million BARDA …

Oct 7, 2024 · ModeX Therapeutics is a clinical-stage biopharmaceutical company developing innovative multispecific biologics for cancer and infectious disease. Its platforms unite the power of multiple biologics in a single molecule to create …See details»

OPKO Health Acquires ModeX Therapeutics, Gains Proprietary

MIAMI, May 09, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical and diagnostics company, today announced the acquisition of …See details»

OPKO Health Acquires ModeX Therapeutics, Gains Proprietary ...

May 9, 2022 · Founded in October 2020 with headquarters in Natick, Mass., ModeX Therapeutics has developed highly flexible multi-specific antibody technology platforms with broad targeting …See details»

ModeX wins $168m BARDA contract to develop viral …

Sep 29, 2023 · ModeX will receive an upfront payment of $59m to fund the Phase I trial, including development, manufacturing, and execution, for the multispecific antibody with a broad ability to neutralise the known variants of the SARS …See details»

ModeX Therapeutics Secures $35 Million BARDA Supplement to …

WESTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ: OPK) company, announces it has been awarded $35 million of …See details»

ModeX Therapeutics Secures BARDA Contract to Develop Novel ...

NATICK, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. company (NASDAQ: OPK), has been awarded a contract from the Biomedical …See details»

ModeX Therapeutics Secures $35 Million BARDA Supplement to …

Oct 7, 2024 · ModeX Therapeutics is a clinical-stage biopharmaceutical company developing innovative multispecific biologics for cancer and infectious disease. Its platforms unite the …See details»

AIDS Clinical Trial Group Presents Results from ... - ModeX …

Mar 5, 2024 · ModeX Therapeutics is a clinical-stage biopharmaceutical company developing innovative multispecific biologics for cancer and infectious disease. Its platforms unite the …See details»

BARDA Continues Partnership with ModeX Therapeutics under …

Oct 7, 2024 · In September 2023, BARDA began collaborating with ModeX Therapeutics to develop a multispecific antibody (mAb) for SARS-CoV-2 pre-exposure prophylaxis (PrEP), …See details»

ModeX nets up to $168M in BARDA bucks to cook up new …

Sep 29, 2023 · The company has hauled in a $168 million contract from the Biomedical Advanced Research and Development Authority (BARDA)—a U.S. Department of Health and Human …See details»

ModeX Therapeutics enters into exclusive worldwide license and ...

Mar 10, 2023 · OPKO Health’s ModeX Therapeutics has entered into an exclusive worldwide license and collaboration agreement with Merck, known as MSD outside the United States and …See details»

AIDS Clinical Trial Group Presents Results from Phase 1 Study of …

Mar 5, 2024 · ModeX Therapeutics is a clinical-stage biopharmaceutical company developing innovative multispecific biologics for cancer and infectious disease. Its platforms unite the …See details»

Covid antibodies shut down variants, earn $35M BARDA bucks

Oct 9, 2024 · In an effort to “box in” SARS-CoV-2, ModeX and partners at the Vaccine Research Center (VRC) have designed multispecific antibodies that they’ve found can neutralize many …See details»

linkstock.net © 2022. All rights reserved